Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Other Non-Current Liabilities: 2021-2023

Historic Other Non-Current Liabilities for Arcturus Therapeutics Holdings (ARCT) over the last 2 years, with Dec 2023 value amounting to $497,000.

  • Arcturus Therapeutics Holdings' Other Non-Current Liabilities fell 82.28% to $497,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $497,000, marking a year-over-year decrease of 82.28%. This contributed to the annual value of $497,000 for FY2023, which is 82.28% down from last year.
  • According to the latest figures from Q4 2023, Arcturus Therapeutics Holdings' Other Non-Current Liabilities is $497,000, which was down 49.08% from $976,000 recorded in Q3 2023.
  • Arcturus Therapeutics Holdings' 5-year Other Non-Current Liabilities high stood at $3.7 million for Q3 2022, and its period low was $358,000 during Q1 2021.
  • In the last 3 years, Arcturus Therapeutics Holdings' Other Non-Current Liabilities had a median value of $1.3 million in 2023 and averaged $1.5 million.
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' Other Non-Current Liabilities skyrocketed by 163.70% in 2022 and then plummeted by 82.28% in 2023.
  • Quarterly analysis of 3 years shows Arcturus Therapeutics Holdings' Other Non-Current Liabilities stood at $1.4 million in 2021, then spiked by 163.70% to $2.8 million in 2022, then tumbled by 82.28% to $497,000 in 2023.
  • Its last three reported values are $497,000 in Q4 2023, $976,000 for Q3 2023, and $1.3 million during Q2 2023.